ATE213952T1 - Freisetzung und mobilisierung hämatopoietischer zellen - Google Patents

Freisetzung und mobilisierung hämatopoietischer zellen

Info

Publication number
ATE213952T1
ATE213952T1 AT94918421T AT94918421T ATE213952T1 AT E213952 T1 ATE213952 T1 AT E213952T1 AT 94918421 T AT94918421 T AT 94918421T AT 94918421 T AT94918421 T AT 94918421T AT E213952 T1 ATE213952 T1 AT E213952T1
Authority
AT
Austria
Prior art keywords
pct
1alpha
mobilization
release
sec
Prior art date
Application number
AT94918421T
Other languages
English (en)
Inventor
Michael Berisford Comer
Matthew John Mccourt
Lars Michael Wood
Michael George Hunter
Richard Mark Edwards
Andrew John Hubert Gearing
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939312343A external-priority patent/GB9312343D0/en
Priority claimed from GB939324252A external-priority patent/GB9324252D0/en
Priority claimed from GB9402188A external-priority patent/GB9402188D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Application granted granted Critical
Publication of ATE213952T1 publication Critical patent/ATE213952T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94918421T 1993-06-15 1994-06-15 Freisetzung und mobilisierung hämatopoietischer zellen ATE213952T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939312343A GB9312343D0 (en) 1993-06-15 1993-06-15 Pharmaceutical use
GB939324252A GB9324252D0 (en) 1993-11-25 1993-11-25 Pharmaceutical use
GB9402188A GB9402188D0 (en) 1994-02-04 1994-02-04 Pharmaceutical use
PCT/GB1994/001284 WO1994028916A1 (en) 1993-06-15 1994-06-15 Release and mobilisation of haematopoietic cells

Publications (1)

Publication Number Publication Date
ATE213952T1 true ATE213952T1 (de) 2002-03-15

Family

ID=27266724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918421T ATE213952T1 (de) 1993-06-15 1994-06-15 Freisetzung und mobilisierung hämatopoietischer zellen

Country Status (8)

Country Link
US (1) US5925568A (de)
EP (1) EP0703784B1 (de)
JP (1) JPH08511263A (de)
AT (1) ATE213952T1 (de)
AU (1) AU6974294A (de)
DE (1) DE69430059T2 (de)
ES (1) ES2172536T3 (de)
WO (1) WO1994028916A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ES2210255T3 (es) * 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
US5595973A (en) * 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells
US6713052B1 (en) 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
GB9600559D0 (en) * 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
EP0848012A1 (de) * 1996-12-13 1998-06-17 Roche Diagnostics GmbH Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999053960A2 (en) * 1998-04-22 1999-10-28 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
SI1016414T1 (en) 1998-12-17 2005-02-28 Applied Research Systems Ars Holding N.V. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
EP1016413A1 (de) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Menschliches Wachstumshormon (HGH) zur Stimulierung der Mobilisierung pluripotenter Hämatopoietischer Stammzellen
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
AU2002219830A1 (en) * 2000-11-10 2002-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
KR20070099013A (ko) * 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 면역 증강제
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
US8846559B2 (en) * 2008-11-03 2014-09-30 Saudi Basic Industries Corporation Stable shape-selective catalyst for aromatic alkylation and methods of using and preparing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809419D0 (en) * 1988-04-21 1988-05-25 Pragnell I Stem cell inhibitors
DK0494268T4 (da) * 1989-09-25 1999-11-08 Genetics Inst Fremgangsmåde til inhibering af stamcellers vækst

Also Published As

Publication number Publication date
AU6974294A (en) 1995-01-03
EP0703784A1 (de) 1996-04-03
WO1994028916A1 (en) 1994-12-22
DE69430059T2 (de) 2002-11-14
ES2172536T3 (es) 2002-10-01
EP0703784B1 (de) 2002-03-06
DE69430059D1 (de) 2002-04-11
US5925568A (en) 1999-07-20
JPH08511263A (ja) 1996-11-26

Similar Documents

Publication Publication Date Title
DE69430059D1 (de) Freisetzung und Mobilisierung hämatopoietischer Zellen
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DK1131410T3 (da) Gensplejsede vævskonstruktioner og fremgangsmåde til fremstilling og anvendelse deraf
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DE69433921D1 (de) Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
FI971756A0 (fi) CD23:een sitoutuvia aineita
ES2161279T3 (es) Nucleosidos y nucleotidos que contienen racimos de boro.
EE9900105A (et) Bensonaftüridiinid bronhiaalravimitena
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ID22801A (id) Bakteri pelapor bioluminesense dan metode-metode untuk memonitor toksisitas dalam sistim-sistim pengolahan secara biologis
ES2162909T3 (es) Composiciones de fosfolipidos silicona modificadas.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ES2177625T3 (es) Citoquina cc-1 humana circulante.
ATE228760T1 (de) Thrombininhibitoren
DE69333962D1 (de) Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
TR200001075T2 (tr) Tiamfenikol ve diklofenak içeren bileşimler.
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
DK0483237T3 (da) Beskyttelse af cytolytisk aktivitet hos NK-celler i PBMC
DK289388D0 (da) Desinfektionsmiddel til at desinficere hud og overflader paa genstande

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties